Contact: +91-9711224068
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal
International Journal of Pharmacy and Pharmaceutical Science

Vol. 6, Issue 1, Part A (2024)

Mechanism, potency and restriction of anti-CTLA-4 and anti-PD-1 immunotherapies in cancer

Author(s):

Ashish Shivram Ramteke

Abstract:

Melanoma and some other cancers identified with high fatality rates which are highly radio and chemotherapy resistant yet may be very immunogenic. These factors have showed to a current surge in research into therapies focusing to boost anticancer immune responses in patients. Beside these therapies, neutralizing antibodies targeting the immune checkpoints cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are being approached as specifically successful. Although, the most of advanced stage melanoma patients ignore, and the search for the “magic bullet” to treat the disease continuously. Anti-PD-1/PD-L1 and anti-CTLA-4 antibodies are the two types of checkpoint inhibitors currently available to melanoma and other cancer patients.

Pages: 10-19  |  43 Views  13 Downloads

How to cite this article:
Ashish Shivram Ramteke. Mechanism, potency and restriction of anti-CTLA-4 and anti-PD-1 immunotherapies in cancer. Int. J. Pharm. Pharm. Sci. 2024;6(1):10-19. DOI: 10.33545/26647222.2024.v6.i1a.75